cyrilzakka/clinical-trials huggingface dataset:
A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)

The objectives of this study are:

To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP).
* Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.

Patients must have:

* Diagnosis of AIDS.
* Weight loss \> 10 percent of premorbid body weight.
* First or second episode of acute Pneumocystis carinii pneumonia (PCP).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Do Not Resuscitate (DNR) status.
* Biliary stasis.

Patients with the following are excluded:

* Do Not Resuscitate (DNR) status.
* Biliary stasis.

Prior Medication:

Excluded within 3 months of study entry:

* Immunomodulators.
* Antiviral new DT
Pulpotomy in Mature Permanent Molars Using Biodentine Versus MTA

The aim of this study is to compare treatment outcomes of pulpotomy in mature permanent teeth using Biodentine versus MTA regarding postoperative pain and success rate.

* Patients will be clinically and radiographically examined and their eligibility will be assessed.
* Eligible patients will be randomly assigned to one of 2 groups: experimental group (pulpotomy using Biodentine) and the control group (pulpotomy using MTA).
* After adminsrtation of local anesthesia, pulpotomy will be done under rubber dam isolation. The pulp tissue will be removed until the level of the orifices of the canals. After hemostasis is achieved, the capping material will be placed. In the experimental group, the capping material is Biodentine while in the control group, the capping material is MTA
* The cavities will be sealed with resin-modified glass ionomer. Then the teeth will be permanently restored with composite . A post-operative radiograph will be taken.
* The patients will be given a pain diary based on Numerical Rating Scale (NRS) and asked to rate their pain level at the specified times.
* The patients will be recalled after 6 and 12 months post-operatively.

Eligibility Criteria:
Inclusion Criteria:

* Patients aging between 18-40 years old
* Patients with symptomatic irreversible pulpitis.
* Radiographically: Absence or slight widening in periodontal ligament space.
* Systemically- healthy patients (ASA I or II).
* Patients who agree to attend for recall appointments and provide written consent.

Exclusion Criteria:

* Severe marginal periodontitis.
* Necrotic pulp, pulp polyp, tooth tender to percussion, clinical progression into periapical abscess, fistula.
* Non-restorable teeth, teeth with internal/external root resorption or root canal calcification.
The Neural Basis of Oxytocin's Effects on Empathy

The main focus of this study is to examine oxytocin effects on behavioral and neural indices of empathy processing.

The neuropeptide oxytocin (OXT) has been demonstrated to modulate empathy in previous behavioural studies. The present study aims at replicating previous findings on OXT on empathy as well as to determine the neural basis of these effects.

In a between-subject, randomized double-blind design, subjects will be either administered intranasal OXT or placebo nasal spray (40 IU). 45 minutes after administration subjects will undergo (fMRI) tasks of empathic processing.

During the tasks subjects will be shown empathy inducing stimuli, and the behavioral and neural response in terms of cognitive, emotional and indirect emotional empathy will be assessed.

Before the administration of treatment, validated questionnaires assessing potential confounding variables, such as depression (Becks Depression Inventory (BDI)) or mood (Positive And Negative Affect Scale (PANAS)) will be administered to the subjects.

Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects without past or current psychiatric or neurological disorders
* no smoking at least 12 hours before experiment
* no alcohol, coffee or other stimulant drinking at least 12 hours before experiment

Exclusion Criteria:

* mental implants
* pregnancy
* uterine cavity operations
* use of medication
* acute physical disorder
Body Mass Index and Initial Presentations of Cardiovascular Diseases

The association between obesity and cardiovascular disease (CVD) has mostly been studied using broad endpoints or have focused on cause-specific mortality. The investigators aim to compare the effect of body mass index (BMI) on different types of initial presentation of CVD.

Obesity has many detrimental effects on the cardiovascular system that can manifest in a range of clinical presentations. Many of these are mediated by frequently coexisting conditions such as diabetes, hypertension and dyslipidemia but there are also direct, progressive effects on the arteries and the heart muscle. As evident from autopsies, even from early adulthood the degree of coronary artery disease (CAD) correlates with the BMI and particularly the amount of abdominal fat. The multiple mechanisms by which obesity exerts its effects are still being elucidated.

Previous studies have assessed the effect of obesity on cause-specific mortality. Here the investigators analyze association of BMI with the first symptomatic presentation of cardiovascular disease across any phenotypes, to which the investigators refer to as "initial presentation" to distinguish from first presentation within a specific phenotype. For example, an initial presentation with myocardial infarction is an MI which is not preceded by stable angina, ischemic stroke or any other phenotype, rather than the first MI in a possible series of MIs, as is commonly used in other studies.

Adjustments The key risk factor of interest is baseline BMI, which the investigators define as the most recent measurement of BMI recorded up to 2 years prior to cohort entry date. BMI will be analyzed based on the following categories: underweight (\<18.5 kg/m2), healthy (18.5 to 24 kg/m2), overweight (25 to 29 kg/m2), moderately obese (30 to 34 kg/m2), morbidly obese (\>35 kg/m2). The healthy BMI category will be used as the reference in regression models.

Associations with BMI will be adjusted for age, sex, ethnicity, social deprivation, smoking, diabetes, and systolic blood pressure, total cholesterol (TCHOL) and high-density lipoprotein cholesterol (HDL). All baseline covariates will be obtained from within a 2 year window prior to study entry.

Statistical analyses Cause-specific Cox models will be used to measure the association between BMI categories and endpoints of interest. Multiple imputation will be used to replace missing values in prognostic factors. The investigators will estimate lifetime risk for each endpoint over time adjusting for competing risks.

Eligibility Criteria:
Inclusion Criteria:

* Baseline age ≥30 years

Exclusion Criteria:

* prior atherosclerotic disease or stroke
P.F.C. Sigma Fixed Versus P.F.C. RP Mobile Bearing Total Knee Systems

This post-market clinical follow-up study was designed to compile long-term knee replacement outcomes of the PFC Sigma fixed and PFC Sigma mobile Rotating Platform (RP) knee systems. The first patient had surgery on November 8, 2001 and the final patient had surgery on July 29, 2005. There were 120 knees consented by a single site, which was the planned sample size in the study protocol, with 117 receiving one of the study devices. The study was terminated as the primary outcome was met and the investigator decided to conduct the study without sponsor support after 2009.

Performance and safety will be assessed using the following surgeon and patient based outcome tools:

1. American Knee Society Knee and Function Scores
2. Knee Society Radiological Analysis
3. Oxford Knee Score
4. SF 12 Score
5. Anterior Knee Pain Score

Specific objectives of the evaluation being to assess the following:

1. Improvement in functional recovery
2. Incidence of anterior knee pain
3. Improvement in Quality of life
4. Incidence of tibial loosening
5. Incidence of excessive polyethylene wear

Eligibility Criteria:
Inclusion Criteria:

1. Administrative - The patient or their authorised representative is able to understand the evaluation, is able to give voluntary written informed consent and will comply with the post operative follow up regime.
2. Age - There are no restrictions relating to age of the patient. The patient's age must be considered suitable by the clinical investigator for a bi-compartmental or tri-compartmental knee arthroplasty using either of the two systems available in the evaluation.
3. Sex - Male or female (providing that they are not pregnant) may be recruited to the evaluation.
4. Diagnosis - patients that require a tri-compartmental knee arthroplasty for primary surgical management of idiopathic osteoarthritis.
5. Suitability - Patients who in the opinion of the Clinical Investigator are considered to be suitable for treatment with a fixed or mobile bearing tibial knee system and are suitable for patella resurfacing.

Exclusion Criteria:

1. Patients with rheumatoid arthritis.
2. Patients requiring revision total knee arthroplasty surgery.
3. Patients with any tibial deformity requiring tibial component augmentation.
4. Patients that in the opinion of the clinical investigators require a constrained prosthesis.
5. Patients with a known history of poor compliance to medical treatment.
6. Patients who are known drug or alcohol abusers.
7. Patients with a pathology which in the opinion of the clinical investigator will adversely affect healing.
8. Patients who are currently participating in another clinical evaluation.
9. Patients with other disorders which in the opinion of the Clinical Investigator will / could impair rehabilitation.
10. Contra-indications for use of the device, as detailed in the package insert.
SUV Max as Predictor of Outcome in Cervical Cancer

Cervical Cancer is staged clinically, not surgically. Patients in whom an extensive disease is identified are not usually eligible for surgery. PET-CT is used to support staging. However, some patients received surgery after staging and subsequently require radio/chemotherapy due to findings on operation.

This study will attempt to find a correlation between SUV-Max on PET-CT and subsequent outcomes i.e. need for adjuvant therapy.


Eligibility Criteria:
Inclusion Criteria:

* having stating PET-CT stored on site
* treated with surgery

Exclusion Criteria:

* not eligible for surgery based on PET-CT, clinical stage
Effect of a Flexibility Program on the Extensibility of the Hamstrings and the Thoracic and Lumbar Spinal Curvatures

The goal of this clinical trial is to analyse the effect of an intervention program based on hamstring flexibility on the extensibility and curvatures of the spine in dancers.

Participants will be dance student with ten years of experience that will undergo a program of stretching four times per week during seven weeks, followed by a detraining period, and a retraining period of three weeks. There will be a pre-test, a post-test and two re-tests after the intervention.

The results will be compared with a control group of dancers that will not take part in the stretching program.

Four measurements were carried out, one before the intervention (pre-test), one after the first stretching programme (post-test), one after a short period of detraining (re-test 1) and the last one at the end of a second period of intervention (re-test 2), analysing the intra-group and inter-group differences for each of the dependent variables.

The sample components (n=61) were divided into two groups following a random distribution carried out by an external researcher. The intervention group (IG), which consisted of 31 dancers, underwent the hamstring stretching programme for a first period of 7 weeks and a second period of 3 weeks after a short period of detraining. The intervention consisted of static and dynamic stretching of the hamstring muscles 4 days per week. The control group (CG), composed of 30 dancers, did not perform the stretching programme. Both groups attended their practical classes in the conservatory. During the detraining period the dancers of both groups took a break from physical exercise.

The variables measured are hamstring extensibility and sagittal spine disposition and pelvic tilt.

Eligibility Criteria:
The inclusion criteria were:

1. students enrolled for at least 18 ECTS credits at the High Conservatory of Dance;
2. previous experience of 10 years in dance;
3. practice dance at least 4 days a week;

(c) not suffer from any chronic pathology or at the time of the study; (d) not practising any other physical exercise apart from dance.

Exclusion criteria:

1. Not attending at least 80% of the practical sessions of the Conservatory throughout the programme;
2. being pregnant at the beginning of the study or getting pregnant during the development of the study;
3. having undergone surgery on the spine or hamstring musculature;
4. having suffered a hamstring injuries in the last year or during the study;
5. having structured spinal disorders;
6. having an injury at the time of the assessment that prevents her from taking the measurements;
7. stretching of the hamstring musculature outside the conservatory.
The Effects of Home Monitors Used with Home Oxygen Therapy

This study\&#39;s purpose is to determine the effects of using monitors with home oxygen therapy (HOT). This trial will test the hypothesis that infants discharged from the neonatal intensive care unit (NICU) with HOT will have a shorter treatment duration if used in conjunction with monitors.

This will be a randomized control trial in which infants being discharged from the neonatal intensive care unit with home oxygen therapy will be placed in one of two groups. Those randomized into the treatment group will be sent home with a monitor to be used continuously during their need for supplemental oxygen. The control group will consist of infants randomized to receive the current standard of care, which is discharge with home oxygen and NO home monitor. The research team will contact the families of the subjects at one-month intervals to collect pertinent data.

Aim 1: Subjects will be randomly assigned to a control group (no home monitors, which is current clinical practice) and an experimental group (home monitors). The investigators will compare the duration of treatment with HOT between groups.

Aim 2: Obtain additional data from study participants to better understand the impact of home monitoring. This data includes frequency of adverse events (defined later in the protocol) including health care utilization, as well as parental quality of life, and altitude of the participant\&#39;s home.

Exploratory Aim 1: Determine the perceptions of families regarding home monitor use.

Eligibility Criteria:
Inclusion Criteria:

* • Infants being discharged with home oxygen therapy.

  * Infants born at other institutions and then transferred to UNMH will be eligible if discharged home with home oxygen therapy.
  * Infants born at gestational age 28 0/7 weeks or greater.
  * Infants of employees of the UNMH will be allowed to participate in the study but will not be targeted. All efforts will be made to ensure that no coercion or undue influence will be used in recruiting this population.

Exclusion Criteria:

* • Infants diagnosed with conditions that will predispose them to prolonged hypoxemia; examples include cardiac anomaly, anatomic anomalies affecting the airway, tracheostomy dependency, cystic fibrosis, and trisomy 21.

  * Infants discharged with hospice care / palliative services.
  * Infants discharged greater than 6 months after they were born.
  * Parents less than 18 years old or prisoners.
  * Parents who are unable to provide consent due to having a legal representative.
  * Infants who are in foster care and/or are wards of the state.
  * Families not fluent in English.
Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA

This is a prospective, single-center, open-label, randomized controlled trial aimed to evaluate the efficacy and safety of entecavir and tenofovir versus entecavir alone in the antiviral treatment of HBV DNA positive B-cell lymphoma patients.

This study plans to enroll about 120 participants in total. Recruitment will last for 2 years.

The study visit will take place on the first day of each cycle of therapy until the end of the treatment.

Participants who meet the inclusion/exclusion criteria were randomly assigned to receive entecavir and tenofovir or entecavir alone after signing the informed consent. HBV DNA will be measured before each cycle of chemotherapy or immunotherapy. When the copy count of HBV DNA drops below 1\*10\^3/L, entecavir single agent will be given orally, until one year after the cycle of therapy.

Treatment response will be evaluated routinely after chemotherapy or immunotherapy.

Within 2 years after the last participant is enrolled, participants' survival information will collected by telephone and/or clinical visit every 3 months after the last visit (i.e. date and cause of death, subsequent cancer treatment, etc.), if there is no withdrawal of the informed consent form.


Eligibility Criteria:
Inclusion Criteria:

* Treatment-naive, pathologically confirmed diagnosis of B-cell lymphomas with the viral load of HBV DNA\>1\*10\^3/L
* Age≥18 years old
* Measurable lesions in radiographic images, defined as at least one well-defined lesions/knots, with both the long diameter and the short diameter≥1.5cm
* Life expectancy of at least 3 months according to researchers' judgement
* Written informed consent must be provided by participants or their legal representatives prior to any research examination or procedure

Exclusion Criteria:

* Creatine\<50mL/min
* Any medical condition that may affect the conduction of this study according to researchers' judgement
Training Intrinsic Foot Muscles

The foot intrinsic muscles are increasingly targeted in foot and ankle rehabilitation. The exercises are often difficult to learn initially. The purpose of the proposed study is to examine the effect training the intrinsic foot muscles on performance in selected physical and functional measures such as balance, plantar pressure during gait, vertical jump, and foot posture. In addition,the investigators will compare one group training with traditional exercise instruction methods and one group using an adjunctive modality (neuromuscular electric stimulation) during the introductory phases of exercise instruction. The investigators are interested in how this modality might affect physical and functional outcome measures and if it affects participants' frustration with learning a new exercise.

Arm 1: The purpose of this arm of the study is to determine if a 4-week trial of foot muscle exercises, instructed with passive, active-assisted, and active techniques, affect functional measures such as balance, plantar pressure during gait, and vertical jump. A frustration index will be employed to assess participant frustration with learning a new exercise. 15 will be enrolled in this arm of the study.

Arm 2: The purpose of this arm of the study is to determine if a 4-week trial of foot muscle exercises, instructed with neuromuscular electric stimulation (NMES) and active techniques, affect functional measures such as balance, plantar pressure during gait, and vertical jump. A frustration index will be employed to assess participant frustration with learning a new exercise.15 will be enrolled in this arm of the study.

Arm 3: This group will not engage in any training, but will serve as a comparator for the two intervention arms.

Eligibility Criteria:
Inclusion Criteria:

* Individuals aged 18-30; Participate in physical activity 3 times/week; No neurologic injury/condition; No prior experience with study exercises; No injury to lower extremity in past 2 months; Inability to selectively extend the great toe while the lesser toes remain quiet (indicating INTRINSIC FOOT MUSCLES dysfunction)

Exclusion Criteria:

* Sedentary; Known neurologic injury or condition; Current LE injury that may affect neuromuscular function; Tarsal coalition; Absolute contradiction to manual therapy or neuromuscular electrical stimulation (NMES); Previous intrinsic foot muscle training protocol
Effects of Dexmedetomidine and Propofol on Pulmonary Mechanics

The aim of this study is to compare the effects of dexmedetomidine and propofol on pulmonary mechanics in intensive care patients.

The aim of this study is to compare the effects propofol and dexmedetomidine on pulmonary mechanics. Sixty patients mechanically ventilated in intensive care unit are included in this study. Patients are divided into two random groups, Group P (propofol) and Group D (dexmedetomidine). Propofol infusion 0.5-2 mg/kg/h is given to Group P patients and dexmedetomidine infusion 0.2-0.7 mcg/kg/h is given to Group D patients for sedation. Initial blood gas analysis, airway resistance (cmH2O/L/sec), positive end-expiratory pressure (PEEP, cmH20), frequency (breath/min), tidal volume (mL/min), minute volume (mL), peak airway pressure (cmH20), compliance (mL/cmH20), endtidal CO2 (mmHg), SvO2 (%) values are recorded. This parameters are evaluated with Drager Evita 4 ventilator and recorded on 5th,15th,30th,45th ve 60th minutes . Sedation is observed using Riker and Ramsey Sedation-Agitation Scale. Compliance of patients to mechanical ventilation is observed and recorded.

The primary outcome measures are airway resistance and peak airway pressure. Secondary outcome measure is sedation score.

Eligibility Criteria:
Inclusion Criteria:

* The patients mechanically ventilated in intensive care unit

Exclusion Criteria:

* Patients with contraindications for using propofol and dexmedetomidine
A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis

Stenosis of the renal graft arteries occurs in 1 to 26% of cases and can damage the graft. Endovascular treatment is first-line treatment. The main objective of this study is to identify the predictive factors of failure of peri-anastomotic.

The aim of this study was to evaluate the post-operative outcomes following endovascular treatment of TRAS (Transplant Renal Artery Stenosis).

This retrospective, monocentric study included patients with peri-anastomotic stenosis of the renal graft from 2000 to 2017. The stenosis is defined by a reduction of at least 50% of the arterial diameter during arteriography. Technical success was defined as residual stenosis less than 30% of the arterial diameter after the procedure.

Eligibility Criteria:
Inclusion Criteria:

* All patients who had a renal transplant from brain-dead donors or from living donors
* All patients who had a Transplant Renal Artery Stenosis

Exclusion Criteria:

* None